This inventor holds 3 USPTO granted patents. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2010-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010-2016
Title: David Earl Kaelin, Jr: Innovator in Pharmaceutical Chemistry
Introduction
David Earl Kaelin, Jr. is a notable inventor based in East Brunswick, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as BACE inhibitors. With a total of three patents to his name, Kaelin's work is focused on addressing critical health issues, including Alzheimer's disease.
Latest Patents
Kaelin's latest patents include innovative compounds designed to inhibit BACE, an enzyme linked to Alzheimer's disease. One of his patents, titled "C6-azaspiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use," presents a range of C2-ring-substituted thiadiazine compounds. These compounds are useful in the treatment and prevention of various pathologies related to Alzheimer's disease. Another significant patent is "C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use." This invention also focuses on C2-ring-substituted iminothiazine compounds, which have potential applications in treating Alzheimer's disease.
Career Highlights
David Kaelin is currently employed at Merck Sharp & Dohme Corporation, a leading global healthcare company. His role involves research and development of pharmaceutical compounds that can lead to breakthroughs in treating neurodegenerative diseases. His expertise in medicinal chemistry has positioned him as a valuable asset in the pharmaceutical industry.
Collaborations
Throughout his career, Kaelin has collaborated with several talented individuals, including Jared N Cumming and Jack D Scott. These collaborations have fostered an environment of innovation and have contributed to the successful development of his patented compounds.
Conclusion
David Earl Kaelin, Jr. is a prominent inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of Alzheimer's disease significantly. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile